Loading clinical trials...
Loading clinical trials...
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).
Conditions
Interventions
Conestat alfa
Locations
5
Brazil
Práxis Pesquisa Medica
São Paulo, Brazil
Hospital Universitario "Dr. José Eleiterio González", Colinia Mitras Centro
Monterrey, Nuevo Leon Mexico, Mexico
University Hospital Basel, Division of Internal Medicine
Basel, Switzerland
Kantonsspital St. Gallen, Klinik für Infektiologie/Spitalhygiene
Sankt Gallen, Switzerland
Stadtspital Triemli, Departement Innere Medizin
Zurich, Switzerland
Start Date
August 6, 2020
Primary Completion Date
September 15, 2021
Completion Date
September 15, 2021
Last Updated
November 9, 2021
NCT06631287
NCT04327570
NCT04262921
NCT05655351
NCT06999018
NCT05800158
Lead Sponsor
University Hospital, Basel, Switzerland
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions